Cargando…

Development and field testing of primary care screening tools for harms of long-term opioid therapy continuation and tapering to discontinuation: a study protocol

INTRODUCTION: Despite calls for screening tools to help providers monitor long-term opioid therapy (LTOT) harms, and identify patients likely to experience harms of discontinuation, such screening tools do not yet exist. Current assessment tools are infeasible to use routinely in primary care and fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Timko, Christine, Kroenke, Kurt, Nevedal, Andrea, Lor, Mai Chee, Oliva, Elizabeth, Drexler, Karen, Sandbrink, Friedhelm, Hoggatt, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499315/
https://www.ncbi.nlm.nih.gov/pubmed/34620670
http://dx.doi.org/10.1136/bmjopen-2021-053524
_version_ 1784580301710688256
author Timko, Christine
Kroenke, Kurt
Nevedal, Andrea
Lor, Mai Chee
Oliva, Elizabeth
Drexler, Karen
Sandbrink, Friedhelm
Hoggatt, Katherine
author_facet Timko, Christine
Kroenke, Kurt
Nevedal, Andrea
Lor, Mai Chee
Oliva, Elizabeth
Drexler, Karen
Sandbrink, Friedhelm
Hoggatt, Katherine
author_sort Timko, Christine
collection PubMed
description INTRODUCTION: Despite calls for screening tools to help providers monitor long-term opioid therapy (LTOT) harms, and identify patients likely to experience harms of discontinuation, such screening tools do not yet exist. Current assessment tools are infeasible to use routinely in primary care and focus mainly on behaviours suggestive of opioid use disorder to the exclusion of other potential harms. This paper describes a study protocol to develop two screening tools that comprise one integrated instrument, Screen to Evaluate and Treat (SET). SET1 will indicate if LTOT may be harmful to continue (yes or no), and SET2 will indicate if tapering to discontinue opioids may be harmful to initiate (yes or no). Patients receiving LTOT who screen positive on the SET tools should receive subsequent additional assessment. SET will give providers methods that are feasible to implement routinely to facilitate more intensive and comprehensive monitoring of patients on LTOT and decision-making about discontinuation. METHODS AND ANALYSIS: We will develop the screening tools, SET1 and SET2, concurrently. Tool development will be done in stages: (1) comprehensive literature searches to yield an initial item pool for domains covered by each screening tool; (2) qualitative item analyses using interviews, expert review and cognitive interviewing, with subsequent item revision, to yield draft versions of each tool; and (3) field testing of the draft screening tools to assess internal consistency, test–retest reliability and convergent and discriminant validity. ETHICS AND DISSEMINATION: Ethical approval was obtained from the Institutional Review Boards of Stanford University and the University of California, San Francisco for the VA Palo Alto Health Care System, and the VA San Francisco Healthcare System, respectively. Findings will be disseminated through peer-reviewed manuscripts and presentations at research conferences.
format Online
Article
Text
id pubmed-8499315
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-84993152021-10-22 Development and field testing of primary care screening tools for harms of long-term opioid therapy continuation and tapering to discontinuation: a study protocol Timko, Christine Kroenke, Kurt Nevedal, Andrea Lor, Mai Chee Oliva, Elizabeth Drexler, Karen Sandbrink, Friedhelm Hoggatt, Katherine BMJ Open Patient-Centred Medicine INTRODUCTION: Despite calls for screening tools to help providers monitor long-term opioid therapy (LTOT) harms, and identify patients likely to experience harms of discontinuation, such screening tools do not yet exist. Current assessment tools are infeasible to use routinely in primary care and focus mainly on behaviours suggestive of opioid use disorder to the exclusion of other potential harms. This paper describes a study protocol to develop two screening tools that comprise one integrated instrument, Screen to Evaluate and Treat (SET). SET1 will indicate if LTOT may be harmful to continue (yes or no), and SET2 will indicate if tapering to discontinue opioids may be harmful to initiate (yes or no). Patients receiving LTOT who screen positive on the SET tools should receive subsequent additional assessment. SET will give providers methods that are feasible to implement routinely to facilitate more intensive and comprehensive monitoring of patients on LTOT and decision-making about discontinuation. METHODS AND ANALYSIS: We will develop the screening tools, SET1 and SET2, concurrently. Tool development will be done in stages: (1) comprehensive literature searches to yield an initial item pool for domains covered by each screening tool; (2) qualitative item analyses using interviews, expert review and cognitive interviewing, with subsequent item revision, to yield draft versions of each tool; and (3) field testing of the draft screening tools to assess internal consistency, test–retest reliability and convergent and discriminant validity. ETHICS AND DISSEMINATION: Ethical approval was obtained from the Institutional Review Boards of Stanford University and the University of California, San Francisco for the VA Palo Alto Health Care System, and the VA San Francisco Healthcare System, respectively. Findings will be disseminated through peer-reviewed manuscripts and presentations at research conferences. BMJ Publishing Group 2021-10-07 /pmc/articles/PMC8499315/ /pubmed/34620670 http://dx.doi.org/10.1136/bmjopen-2021-053524 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Patient-Centred Medicine
Timko, Christine
Kroenke, Kurt
Nevedal, Andrea
Lor, Mai Chee
Oliva, Elizabeth
Drexler, Karen
Sandbrink, Friedhelm
Hoggatt, Katherine
Development and field testing of primary care screening tools for harms of long-term opioid therapy continuation and tapering to discontinuation: a study protocol
title Development and field testing of primary care screening tools for harms of long-term opioid therapy continuation and tapering to discontinuation: a study protocol
title_full Development and field testing of primary care screening tools for harms of long-term opioid therapy continuation and tapering to discontinuation: a study protocol
title_fullStr Development and field testing of primary care screening tools for harms of long-term opioid therapy continuation and tapering to discontinuation: a study protocol
title_full_unstemmed Development and field testing of primary care screening tools for harms of long-term opioid therapy continuation and tapering to discontinuation: a study protocol
title_short Development and field testing of primary care screening tools for harms of long-term opioid therapy continuation and tapering to discontinuation: a study protocol
title_sort development and field testing of primary care screening tools for harms of long-term opioid therapy continuation and tapering to discontinuation: a study protocol
topic Patient-Centred Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499315/
https://www.ncbi.nlm.nih.gov/pubmed/34620670
http://dx.doi.org/10.1136/bmjopen-2021-053524
work_keys_str_mv AT timkochristine developmentandfieldtestingofprimarycarescreeningtoolsforharmsoflongtermopioidtherapycontinuationandtaperingtodiscontinuationastudyprotocol
AT kroenkekurt developmentandfieldtestingofprimarycarescreeningtoolsforharmsoflongtermopioidtherapycontinuationandtaperingtodiscontinuationastudyprotocol
AT nevedalandrea developmentandfieldtestingofprimarycarescreeningtoolsforharmsoflongtermopioidtherapycontinuationandtaperingtodiscontinuationastudyprotocol
AT lormaichee developmentandfieldtestingofprimarycarescreeningtoolsforharmsoflongtermopioidtherapycontinuationandtaperingtodiscontinuationastudyprotocol
AT olivaelizabeth developmentandfieldtestingofprimarycarescreeningtoolsforharmsoflongtermopioidtherapycontinuationandtaperingtodiscontinuationastudyprotocol
AT drexlerkaren developmentandfieldtestingofprimarycarescreeningtoolsforharmsoflongtermopioidtherapycontinuationandtaperingtodiscontinuationastudyprotocol
AT sandbrinkfriedhelm developmentandfieldtestingofprimarycarescreeningtoolsforharmsoflongtermopioidtherapycontinuationandtaperingtodiscontinuationastudyprotocol
AT hoggattkatherine developmentandfieldtestingofprimarycarescreeningtoolsforharmsoflongtermopioidtherapycontinuationandtaperingtodiscontinuationastudyprotocol